Position paper of the National Osteoporosis Foundation of South Africa (NOFSA) on the use of parathyroid hormone (PTH 1-34) in the treatment of osteoporosis.
Hough
Stephen
S
Ascott-Evans
Brynne
B
de Villiers
Tobie
T
de Weerd
Jan
J
Ellis
Graham
G
Lipschitz
Stan
S
D000368:Aged; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D018579:Patient Selection; D011379:Prognosis; D018570:Risk Assessment; D013019:South Africa; D016896:Treatment Outcome
D010281:Parathyroid Hormone